DK159489D0 - Hidtil ukendte antistof-heterokonjugater - Google Patents

Hidtil ukendte antistof-heterokonjugater

Info

Publication number
DK159489D0
DK159489D0 DK159489A DK159489A DK159489D0 DK 159489 D0 DK159489 D0 DK 159489D0 DK 159489 A DK159489 A DK 159489A DK 159489 A DK159489 A DK 159489A DK 159489 D0 DK159489 D0 DK 159489D0
Authority
DK
Denmark
Prior art keywords
heteroconjugates
lymphocytes
antibody
heteroconjugate
resulting
Prior art date
Application number
DK159489A
Other languages
English (en)
Other versions
DK173382B1 (da
DK159489A (da
Inventor
Jeffrey A Ledbetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of DK159489D0 publication Critical patent/DK159489D0/da
Publication of DK159489A publication Critical patent/DK159489A/da
Application granted granted Critical
Publication of DK173382B1 publication Critical patent/DK173382B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Coating With Molten Metal (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198901594A 1988-04-04 1989-04-03 Hidtil ukendte heterokonjugater og bispecifikke antistoffer DK173382B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17682588A 1988-04-04 1988-04-04
US17682588 1988-04-04
US27193488A 1988-11-14 1988-11-14
US27193488 1988-11-14

Publications (3)

Publication Number Publication Date
DK159489D0 true DK159489D0 (da) 1989-04-03
DK159489A DK159489A (da) 1989-10-05
DK173382B1 DK173382B1 (da) 2000-09-11

Family

ID=26872636

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198901594A DK173382B1 (da) 1988-04-04 1989-04-03 Hidtil ukendte heterokonjugater og bispecifikke antistoffer

Country Status (20)

Country Link
EP (1) EP0336379B1 (da)
JP (1) JP2613106B2 (da)
KR (1) KR100205833B1 (da)
CN (1) CN1058296C (da)
AT (1) ATE133866T1 (da)
AU (1) AU629204B2 (da)
DE (1) DE68925593T2 (da)
DK (1) DK173382B1 (da)
ES (1) ES2083960T3 (da)
FI (1) FI105320B (da)
GR (1) GR3019224T3 (da)
HU (1) HU213576B (da)
IE (1) IE72187B1 (da)
IL (1) IL89823A (da)
MY (1) MY106592A (da)
NO (1) NO178699C (da)
NZ (1) NZ228560A (da)
PT (1) PT90195B (da)
YU (1) YU68589A (da)
ZA (1) ZA892448B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JPH05268986A (ja) * 1990-03-19 1993-10-19 Bristol Myers Squibb Co モノクローナル抗体及びリンパ球の活性法
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE69227623T2 (de) * 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
EP0945139A1 (en) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Methods and means for the treatment of immune related diseases such as Graft vs. Host disease
AU783250B2 (en) * 1999-06-17 2005-10-06 Dartmouth College Autologous adoptive immunotherapy with primed antigen-specific T cells or B cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DE10034607A1 (de) 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP4103609A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4378529A1 (en) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy involving effector cell engagement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
EP0153871A3 (en) * 1984-03-01 1987-07-01 Centocor, Inc. Antibody enhancement of immunogenicity of antigen
JPH0617909B2 (ja) * 1984-04-23 1994-03-09 ボストン バイオメディカル リサーチ インスティテュート，インコーポレイテッド 双特異性抗体決定子
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.

Also Published As

Publication number Publication date
JPH01304356A (ja) 1989-12-07
DK173382B1 (da) 2000-09-11
CN1058296C (zh) 2000-11-08
IL89823A0 (en) 1989-12-15
IE891054L (en) 1989-10-04
YU68589A (en) 1991-10-31
CN1036988A (zh) 1989-11-08
ES2083960T3 (es) 1996-05-01
HU213576B (en) 1997-08-28
KR890015751A (ko) 1989-11-25
DE68925593D1 (de) 1996-03-21
ATE133866T1 (de) 1996-02-15
GR3019224T3 (en) 1996-06-30
DK159489A (da) 1989-10-05
PT90195B (pt) 1994-06-30
NO891375L (no) 1989-10-05
JP2613106B2 (ja) 1997-05-21
NO178699B (no) 1996-02-05
ZA892448B (en) 1989-12-27
AU629204B2 (en) 1992-10-01
AU3242389A (en) 1989-10-05
NZ228560A (en) 1991-10-25
EP0336379A3 (en) 1990-01-31
NO891375D0 (no) 1989-03-31
FI891528L (fi) 1989-10-05
MY106592A (en) 1995-06-30
HUT51338A (en) 1990-04-28
KR100205833B1 (ko) 1999-07-01
FI105320B (fi) 2000-07-31
DE68925593T2 (de) 1996-06-13
EP0336379A2 (en) 1989-10-11
EP0336379B1 (en) 1996-02-07
IL89823A (en) 1994-07-31
PT90195A (pt) 1989-11-10
NO178699C (no) 1996-05-15
FI891528A0 (fi) 1989-03-30
IE72187B1 (en) 1997-03-26

Similar Documents

Publication Publication Date Title
DK159489D0 (da) Hidtil ukendte antistof-heterokonjugater
ATE47155T1 (de) Monoklonaler antikoerper.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
IL88248A (en) Solid phase immunoassay for detecting hiv antigens using kc-57 monoclonal antibody, and kit for the performance thereof
NO913271L (no) Cdr-podete antistoffer.
MX9101117A (es) Anticuerpos modificados y su preparacion
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
ATE45285T1 (de) Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
BR8003501A (pt) Aperfeicoamento no processo de determinacao de um antigeno, anticorpo ou complexo ou conjugado de antigeno-anticorpo, e um conjunto de reagentes para determinacao de reacao de aglutinacao imunoquimica
NO174153C (no) Antigen og monoklonalt antistoff for anvendelse in vitro, samt immunologiske reagenser inneholdende disse
ATE132267T1 (de) Immuntest unter verwendung von antigenen, produziert in heterologen organismen
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DK673789A (da) Monoklonalt antistof, som specifikt binder til kc-48-antigenet i neutrophiler og eosinophiler, samt hybridomocellelinie, som producerer antistoffet
NO900216D0 (no) Anti-idiotype antistoff mot anti-human melanom-assosiert antigen med hoey molekylvekt.
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.
NO903788D0 (no) Monoklonalt antistoff mot protein c.

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK